<SEC-DOCUMENT>0001209191-21-052851.txt : 20210820
<SEC-HEADER>0001209191-21-052851.hdr.sgml : 20210820
<ACCEPTANCE-DATETIME>20210820190653
ACCESSION NUMBER:		0001209191-21-052851
CONFORMED SUBMISSION TYPE:	3/A
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20210811
FILED AS OF DATE:		20210820
DATE AS OF CHANGE:		20210820

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Vanhove Geertrui
		CENTRAL INDEX KEY:			0001771994

	FILING VALUES:
		FORM TYPE:		3/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39635
		FILM NUMBER:		211194946

	MAIL ADDRESS:	
		STREET 1:		1333 S. SPECTRUM BLVD #100
		CITY:			CHANDLER
		STATE:			AZ
		ZIP:			85286

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Surrozen, Inc./DE
		CENTRAL INDEX KEY:			0001824893
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				981556622
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		171 OYSTER POINT BLVD
		STREET 2:		SUITE 400
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-475-2820

	MAIL ADDRESS:	
		STREET 1:		171 OYSTER POINT BLVD
		STREET 2:		SUITE 400
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Consonance-HFW Acquisition Corp.
		DATE OF NAME CHANGE:	20200915
</SEC-HEADER>
<DOCUMENT>
<TYPE>3/A
<SEQUENCE>1
<FILENAME>doc3a.xml
<DESCRIPTION>FORM 3/A SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3/A</documentType>

    <periodOfReport>2021-08-11</periodOfReport>

    <dateOfOriginalSubmission>2021-08-16</dateOfOriginalSubmission>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001824893</issuerCik>
        <issuerName>Surrozen, Inc./DE</issuerName>
        <issuerTradingSymbol>SRZN</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001771994</rptOwnerCik>
            <rptOwnerName>Vanhove Geertrui</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O SURROZEN, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>171 OYSTER POINT BLVD., SUITE 400</rptOwnerStreet2>
            <rptOwnerCity>SOUTH SAN FRANCISCO</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94080</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Medical Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Employee Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>1.25</value>
                <footnoteId id="F3"/>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2029-05-16</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>108902</value>
                    <footnoteId id="F2"/>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Employee Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>10.76</value>
                <footnoteId id="F3"/>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F4"/>
            </exerciseDate>
            <expirationDate>
                <value>2031-02-22</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>26347</value>
                    <footnoteId id="F2"/>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Twenty-five percent of the shares subject to the Stock Option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years.</footnote>
        <footnote id="F2">Received pursuant to the Business Combination Agreement (the &quot;BCA&quot;), dated April 15, 2021, by and among the Issuer (fka &quot;Consonance-HFW Acquisition Corp&quot;), Perseverance Merger Sub Inc. (&quot;Merger Sub&quot;), and Surrozen, Inc. (the &quot;Original Surrozen&quot;). Under the terms of the BCA, among other things, Merger Sub merged with and into the Original Surrozen, with Original Surrozen surviving as a wholly-owned subsidiary of the Issuer (the &quot;Business Combination&quot;), the Original Surrozen changed its name to Surrozen Operating, Inc., and the Issuer changed its name to Surrozen, Inc.  In addition, per the terms of the BCA, each share and equity award of the Original Surrozen outstanding as of effective time of the Business Combination was exchanged for shares of the Issuer's Common Stock or comparable equity awards that are settled or are exercisable for shares of the Issuer's Common Stock, as applicable, at the exchange ratio of 0.175648535.</footnote>
        <footnote id="F3">This amendment is being filed to correct a typographical error in the exercise prices of the Stock Options which were incorrectly reported on the original filed Form 3.</footnote>
        <footnote id="F4">1/48th of the shares subject to the Stock Option shall vest on each monthly anniversary of the vesting commencement date over a four-year period.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Sheela Mohan-Peterson, Attorney-in-Fact for Geertrui Vanhove</signatureName>
        <signatureDate>2021-08-18</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
